Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
CWP232291 blocks proliferation of cancer cells via activation of caspases. Active caspase
have been shown to target beta-catenin, the hallmark of canonical Wnt signaling, for
degradation through caspase-directed cleavage. CWP232291 targets beta-catenin for degradation
and thereby inhibits the expression of cell cycle and anti-apoptotic genes such as cyclin D1
and survivin.